US20040192911A1 - Process for the preparation of an indole derivative - Google Patents
Process for the preparation of an indole derivative Download PDFInfo
- Publication number
- US20040192911A1 US20040192911A1 US10/818,301 US81830104A US2004192911A1 US 20040192911 A1 US20040192911 A1 US 20040192911A1 US 81830104 A US81830104 A US 81830104A US 2004192911 A1 US2004192911 A1 US 2004192911A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- indole
- oxazino
- dihydro
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 150000002475 indoles Chemical class 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 14
- IJQYPUZBTYDSGN-UHFFFAOYSA-N methyl 2-(3-chloropropoxy)-1h-indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=C(OCCCCl)NC2=C1 IJQYPUZBTYDSGN-UHFFFAOYSA-N 0.000 claims abstract description 8
- LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 claims abstract description 6
- -1 butyl-4-piperidyl Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- JOPOHNNCBFYVIM-UHFFFAOYSA-N methyl 3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=C2N1CCCO2 JOPOHNNCBFYVIM-UHFFFAOYSA-N 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- KVCSJPATKXABRQ-UHFFFAOYSA-N piboserod Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KVCSJPATKXABRQ-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QXAUTQFAWKKNLM-UHFFFAOYSA-N methyl indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CNC2=C1 QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 description 4
- KGPKGZANCRJSKC-UHFFFAOYSA-N CC(=O)C1=C2OCCCN2C2=C1C=CC=C2 Chemical compound CC(=O)C1=C2OCCCN2C2=C1C=CC=C2 KGPKGZANCRJSKC-UHFFFAOYSA-N 0.000 description 3
- SBXYTQUGWXISRE-UHFFFAOYSA-N COC(=O)C1(Cl)C=NC2=C1C=CC=C2 Chemical compound COC(=O)C1(Cl)C=NC2=C1C=CC=C2 SBXYTQUGWXISRE-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- SFVBLYFWLHRAIV-UHFFFAOYSA-N CN1CCC(CNC(=O)C2=C3OCCCN3C3=C2C=CC=C3)CC1 Chemical compound CN1CCC(CNC(=O)C2=C3OCCCN3C3=C2C=CC=C3)CC1 SFVBLYFWLHRAIV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 0 *OC(c1c2OCCC[n]2c2ccccc12)=O Chemical compound *OC(c1c2OCCC[n]2c2ccccc12)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- This invention relates to a new synthetic process to a compound having pharmacological activity.
- WO 93/18036 (SmithKline Beecham plc) describes certain indole compounds having 5-HT 4 receptor antagonist activity including the compound of formula (I)
- This compound is N-[(1- n butyl-4-piperidyl) methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide, referred to herein by its code number SB-207266, (the hydrochloride salt is SB-207266-A), which is being developed by SmithKline Beecham plc as the active ingredient in a medicament for treatment of irritable bowel syndrome.
- Example 3 of WO 93/18036 describes a method of preparation of SB-207266-A from N-[(1- n butyl-4-piperidyl)methyl]indole-3-carboxamide (i.e. the compound corresponding to SB-207266, without the oxazino moiety), by reacting with N-chlorosuccinimide and 3-bromo-1-propanol, followed by treatment with sodium carbonate.
- N-[(1- n butyl-4-piperidyl)methyl]indole-3-carboxamide is prepared by coupling N-(1- n butyl-4-piperidyl)methylamine with a indole-3-carboxylic acid.
- WO 98/07728 (SmithKline Beecham plc) describes a process for preparing SB-207266-A which involves the use of the N-(1- n butyl-4-piperidyl)methylamine intermediate at a later stage in the process thus resulting in an increased yield of SB-207266-A relative to the amount of this intermediate, which is relatively expensive to produce.
- the alternative process comprises the reaction of of N-(1- n butyl-4-piperidyl)methylamine with a compound of formula (A):
- R is alkyl, such as methyl or ethyl.
- WO98/07728 also describes the preparation of the oxazinoindole compound of the formula (A) from the corresponding indole by reaction with N-chlorosuccinimide and a 3-halo-propanol, such as 3-chloropropanol or 3-bromopropanol followed by cyclisation of the intermediate (B) by treatment with base in a suitable solvent.
- the reaction is conveniently effected in an organic solvent such as dichloromethane or chloroform, at a temperature in the range ⁇ 20° C. to +10° C., for example using a catalytic amount of the acid.
- the resulting product of formula (B) can be used for the next stage in the synthesis of SB-207266 e.g as described in WO 98/07728.
- a mixture of methyl indole-3-carboxylate and dichloromethane is cooled to 0° C.
- 1,4-dimethylpiperazine (0.55 eq.) and N-chlorosuccinimide (1.1 eq) are added and the mixture left to stir for two hours to give a slurry containing the compound of formula (C) above.
- the resulting slurry is added to a solution of 3-chloropropanol (1.1 eq) and trichloroacetic acid (0.12 eq) in dichloromethane, maintaining the temperature below 0° C.
- reaction mixture is left to stir for half an hour, then washed with 10% aqueous sodium carbonate, 0.5 M hydrochloric acid and water.
- the organic solution is dried over sodium sulphate, filtered and the solvent evaporated.
- Toluene is added and the mixture stirred at 0-5° C. for one hour.
- the product is then filtered, washed with toluene and dried to give the title product in 83% yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.
Description
- This invention relates to a new synthetic process to a compound having pharmacological activity.
- WO 93/18036 (SmithKline Beecham plc) describes certain indole compounds having 5-HT 4 receptor antagonist activity including the compound of formula (I)
- and its pharmaceutically acceptable salts. This compound is N-[(1- nbutyl-4-piperidyl) methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide, referred to herein by its code number SB-207266, (the hydrochloride salt is SB-207266-A), which is being developed by SmithKline Beecham plc as the active ingredient in a medicament for treatment of irritable bowel syndrome.
- Example 3 of WO 93/18036 describes a method of preparation of SB-207266-A from N-[(1- nbutyl-4-piperidyl)methyl]indole-3-carboxamide (i.e. the compound corresponding to SB-207266, without the oxazino moiety), by reacting with N-chlorosuccinimide and 3-bromo-1-propanol, followed by treatment with sodium carbonate. N-[(1-nbutyl-4-piperidyl)methyl]indole-3-carboxamide is prepared by coupling N-(1-nbutyl-4-piperidyl)methylamine with a indole-3-carboxylic acid.
- WO 98/07728 (SmithKline Beecham plc) describes a process for preparing SB-207266-A which involves the use of the N-(1- nbutyl-4-piperidyl)methylamine intermediate at a later stage in the process thus resulting in an increased yield of SB-207266-A relative to the amount of this intermediate, which is relatively expensive to produce. In particular, the alternative process comprises the reaction of of N-(1-nbutyl-4-piperidyl)methylamine with a compound of formula (A):
- wherein R is alkyl, such as methyl or ethyl.
- The compound of formula (A) wherein R is methyl is methyl 3,4-dihydro-2H-[1,3]-oxazino[3,2-α]indole-10-carboxylate.
- WO98/07728 also describes the preparation of the oxazinoindole compound of the formula (A) from the corresponding indole by reaction with N-chlorosuccinimide and a 3-halo-propanol, such as 3-chloropropanol or 3-bromopropanol followed by cyclisation of the intermediate (B) by treatment with base in a suitable solvent.
- The Description in the latter specification describes in more detail the the preparation of compound (B) from the corresponding methyl indole-3-carboxylate by reaction of the latter with N-chlorosuccinimide in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to form an intermediate of formula (C):
- and subsequent reaction of (C) with 3-chloropropanol in the presence of methanesulphonic acid.
- We have now found that the use of an acid having a pKa of from 0 to 2, especially trichloroacetic acid, in place of methanesulphonic acid results in significant advantages for the commercial operation of the process.
- According to a feature of the present invention we provide a process for the preparation of the compound of formula (B) above, namely methyl 2-(3-chloropropoxy)-inodole-3-carboxylate, which comprises reacting a compound of formula (C) with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2, especially trichloroacetic acid.
- Other acids which may be used in accordance with the invention in addition to trichloroacetic acid include dichloroacetic acid and trifluoroacetic acid.
- The use of the above-defined acid such as trichloroacetic acid in place of methanesulphonic acid has been found to increase significantly the overall yield of the process. The former acid also has the advantage over the latter that its use results in the formation of lower levels of the corresponding 2-methoxy compound, as an impurity.
- The reaction is conveniently effected in an organic solvent such as dichloromethane or chloroform, at a temperature in the range −20° C. to +10° C., for example using a catalytic amount of the acid. The resulting product of formula (B) can be used for the next stage in the synthesis of SB-207266 e.g as described in WO 98/07728.
- The following Example illustrates the invention.
- A mixture of methyl indole-3-carboxylate and dichloromethane is cooled to 0° C. 1,4-dimethylpiperazine (0.55 eq.) and N-chlorosuccinimide (1.1 eq) are added and the mixture left to stir for two hours to give a slurry containing the compound of formula (C) above. The resulting slurry is added to a solution of 3-chloropropanol (1.1 eq) and trichloroacetic acid (0.12 eq) in dichloromethane, maintaining the temperature below 0° C. The reaction mixture is left to stir for half an hour, then washed with 10% aqueous sodium carbonate, 0.5 M hydrochloric acid and water. The organic solution is dried over sodium sulphate, filtered and the solvent evaporated. Toluene is added and the mixture stirred at 0-5° C. for one hour. The product is then filtered, washed with toluene and dried to give the title product in 83% yield.
Claims (22)
1 and 2 (Cancelled)
3. A process for preparing N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide, i.e. the compound of Formula (I):
or a pharmaceutically acceptable salt thereof, which process comprises
(a) preparing methyl 2-(3-chloropropoxy)-indole-3-carboxylate, i.e. the compound of formula (B):
by reacting a compound of formula (C)
with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2; and
(b) using the resulting methyl 2-(3-chloropropoxy)-indole-3-carboxylate of formula (B) in the next stage in the synthesis of the N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or the pharmaceutically acceptable salt thereof.
4. A process as claimed in claim 3 wherein in step (a) the acid is trichloroacetic acid, dichloroacetic acid and/or trifluoroacetic acid.
5. A process as claimed in claim 3 wherein in step (a) the acid is trichloroacetic acid.
6. A process as claimed in claim 3 wherein the reaction in step (a) is effected in an organic solvent.
7. A process as claimed in claim 6 wherein in step (a) the organic solvent is dichloromethane or chloroform.
8. A process as claimed in claim 3 wherein the reaction in step (a) is effected in an organic solvent at a temperature in the range −20° C. to +10° C.
9. A process as claimed in claim 4 wherein the reaction in step (a) is effected in an organic solvent at a temperature in the range −20° C. to +10° C.
10. A process as claimed in claim 8 wherein in step (a) the organic solvent is dichloromethane or chloroform.
11. A process as claimed in claim 9 wherein in step (a) the organic solvent is dichloromethane or chloroform.
12. A process as claimed in claim 6 wherein the reaction in step (a) is effected using a catalytic amount of the acid.
13. A process as claimed in claim 8 wherein the reaction in step (a) is effected using a catalytic amount of the acid.
14. A process as claimed in claim 9 wherein the reaction in step (a) is effected using a catalytic amount of the acid.
15. A process as claimed in claim 11 wherein the reaction in step (a) is effected using a catalytic amount of the acid.
16. A process as claimed in claim 3 comprising, in step (b), cyclisation of the intermediate (B) (the methyl 2-(3-chloropropoxy)-indole-3-carboxylate) by treatment with base in a solvent to prepare a compound of formula (A):
wherein R is methyl, which compound of formula (A) is methyl 3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxylate.
17. A process as claimed in claim 16 , comprising, in step (b): reacting N-(1-nbutyl-4-piperidyl)methylamine with the methyl 3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxylate of formula (A) to prepare the N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide of formula (I); and
optionally preparing a pharmaceutically acceptable salt of the N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide.
18. A process as claimed in claim 13 comprising, in step (b), cyclisation of the intermediate (B) (the methyl 2-(3-chloropropoxy)-indole-3-carboxylate) by treatment with base in a solvent to prepare a compound of formula (A):
wherein R is methyl, which compound of formula (A) is methyl 3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxylate.
19. A process as claimed in claim 18 , comprising, in step (b): reacting N-(1-nbutyl-4-piperidyl)methylamine with the methyl 3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxylate of formula (A) to prepare the N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide of formula (I); and
optionally preparing a pharmaceutically acceptable salt of the N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide.
20. A process as claimed in claim 3 , wherein step (b) comprises preparing the hydrochloride salt of N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide.
21. A process as claimed in claim 13 , wherein step (b) comprises preparing the hydrochloride salt of N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB-207266-A).
22. A process as claimed in claim 17 , wherein step (b) comprises preparing the hydrochloride salt of N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB-207266-A).
23. A process as claimed in claim 19 , wherein step (b) comprises preparing the hydrochloride salt of N-[(1-nbutyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/818,301 US20040192911A1 (en) | 1998-07-16 | 2004-04-05 | Process for the preparation of an indole derivative |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815481.8A GB9815481D0 (en) | 1998-07-16 | 1998-07-16 | Pharmaceuticals |
| GB9815481.8 | 1998-07-16 | ||
| US74382001A | 2001-03-28 | 2001-03-28 | |
| US10/094,285 US20020091271A1 (en) | 1998-07-16 | 2002-03-08 | Process for the preparation of an indole derivative |
| US10/354,865 US6946565B2 (en) | 1998-07-16 | 2003-01-30 | Process for the preparation of an indole derivative |
| US10/818,301 US20040192911A1 (en) | 1998-07-16 | 2004-04-05 | Process for the preparation of an indole derivative |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/354,865 Division US6946565B2 (en) | 1998-07-16 | 2003-01-30 | Process for the preparation of an indole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040192911A1 true US20040192911A1 (en) | 2004-09-30 |
Family
ID=26314042
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/094,285 Abandoned US20020091271A1 (en) | 1998-07-16 | 2002-03-08 | Process for the preparation of an indole derivative |
| US10/308,474 Expired - Fee Related US6583294B2 (en) | 1998-07-16 | 2002-12-03 | Process for the preparation of an indole derivative |
| US10/354,865 Expired - Fee Related US6946565B2 (en) | 1998-07-16 | 2003-01-30 | Process for the preparation of an indole derivative |
| US10/818,301 Abandoned US20040192911A1 (en) | 1998-07-16 | 2004-04-05 | Process for the preparation of an indole derivative |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/094,285 Abandoned US20020091271A1 (en) | 1998-07-16 | 2002-03-08 | Process for the preparation of an indole derivative |
| US10/308,474 Expired - Fee Related US6583294B2 (en) | 1998-07-16 | 2002-12-03 | Process for the preparation of an indole derivative |
| US10/354,865 Expired - Fee Related US6946565B2 (en) | 1998-07-16 | 2003-01-30 | Process for the preparation of an indole derivative |
Country Status (1)
| Country | Link |
|---|---|
| US (4) | US20020091271A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060094715A1 (en) * | 2002-05-16 | 2006-05-04 | Levy Finn O | 5-Ht4 receptor antagonists for the treatment of heart failure |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020091271A1 (en) * | 1998-07-16 | 2002-07-11 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
| AU2003270343A1 (en) * | 2002-08-30 | 2004-03-19 | Aethon, Inc. | Robotic cart pulling vehicle |
| US7313421B2 (en) * | 2004-09-28 | 2007-12-25 | G2 Microsystems Pty. Ltd. | GPS receiver having RF front end power management and simultaneous baseband searching of frequency and code chip offset |
| CA2864027C (en) * | 2005-10-14 | 2017-05-02 | Aldo Zini | Robotic ordering and delivery apparatuses, systems and methods |
| CA2831832C (en) | 2011-04-11 | 2021-06-15 | Crown Equipment Limited | Method and apparatus for efficient scheduling for multiple automated non-holonomic vehicles using a coordinated path planner |
| US20140058634A1 (en) | 2012-08-24 | 2014-02-27 | Crown Equipment Limited | Method and apparatus for using unique landmarks to locate industrial vehicles at start-up |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US6100397A (en) * | 1996-08-16 | 2000-08-08 | Smithkline Beecham Plc | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process |
| US20020091271A1 (en) * | 1998-07-16 | 2002-07-11 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG50693A1 (en) | 1992-03-12 | 1998-07-20 | Smithkline Beecham Plc | Pharmaceuticals |
| CA2263480C (en) | 1996-08-16 | 2007-03-06 | Smithkline Beecham P.L.C. | Process for the preparation of n-[(1-nbutyl-4-piperidyl)methyl] -3,4-dihydro -2h-[1,3] oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process |
| GB9618967D0 (en) | 1996-09-11 | 1996-10-23 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9725933D0 (en) | 1997-12-05 | 1998-02-04 | Smithkline Beecham Plc | Pharmaceuticals |
| GB2336342B (en) | 1998-04-14 | 2001-10-17 | Agco Sa | Hood assembly |
| GB9815483D0 (en) | 1998-07-16 | 1998-09-16 | Smithkline Beecham Plc | Pharmaceuticals |
-
2002
- 2002-03-08 US US10/094,285 patent/US20020091271A1/en not_active Abandoned
- 2002-12-03 US US10/308,474 patent/US6583294B2/en not_active Expired - Fee Related
-
2003
- 2003-01-30 US US10/354,865 patent/US6946565B2/en not_active Expired - Fee Related
-
2004
- 2004-04-05 US US10/818,301 patent/US20040192911A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US6100397A (en) * | 1996-08-16 | 2000-08-08 | Smithkline Beecham Plc | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process |
| US20020091271A1 (en) * | 1998-07-16 | 2002-07-11 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
| US6583294B2 (en) * | 1998-07-16 | 2003-06-24 | Smithkline Beecham P.L.C. | Process for the preparation of an indole derivative |
| US6946565B2 (en) * | 1998-07-16 | 2005-09-20 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060094715A1 (en) * | 2002-05-16 | 2006-05-04 | Levy Finn O | 5-Ht4 receptor antagonists for the treatment of heart failure |
| US20090169545A1 (en) * | 2002-05-16 | 2009-07-02 | Serodus As | 5-ht4 receptor antagonists for the treatment of heart failure |
| US8829028B2 (en) | 2002-05-16 | 2014-09-09 | Serodus As | 5-HT4 receptor antagonists for the treatment of heart failure |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020091271A1 (en) | 2002-07-11 |
| US20030083506A1 (en) | 2003-05-01 |
| US6583294B2 (en) | 2003-06-24 |
| US20030114684A1 (en) | 2003-06-19 |
| US6946565B2 (en) | 2005-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505373A (en) | Biphenyl derivatives, their preparation and use as pharmaceuticals | |
| JPH09151174A (en) | Benzonitriles and benzofluorides | |
| US6583294B2 (en) | Process for the preparation of an indole derivative | |
| JP3911297B2 (en) | N-[(1-nbutyl-4-piperidyl) methyl] -3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide and salts and intermediates in the production | |
| EP1097136B1 (en) | Process for the preparation of an indole derivative | |
| EP1097135B1 (en) | Process for the preparation of an indole derivative | |
| AU725210B2 (en) | Preparation of 1-butyl-4-piperidinylmethylamine | |
| US6100397A (en) | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process | |
| HU180371B (en) | Process for producing n-bracket-amino-alkyl-bracket closed-indole derivatives | |
| HK1020963B (en) | Preparation of 1-butyl-4-piperidinylmethylamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |